Panel Community Conversations track
The Weight of Hepatotoxicity: Liver Injury in the Age of Weight Loss Therapies
Sat, Nov 7, 2026 · 3:45–4:45 PM MST Convention Center: Bluebird Ballroom 3DEF, Colorado Convention Center
About this session
The exponential global rise in type 2 diabetes, obesity, and metabolic dysfunction–associated steatohepatitis (MASH) has driven the pursuit of increasingly effective therapies. Glucagon-like peptide-1 receptor agonsits (GLP-1 RAs) have revolutionaled the management of these diseases but are not without risk. While rare, liver injury potentially associated with GLP-1 RA use is becoming more widely known; it is an increasing concern for drug developers as well as clinicians and their patients.
Speakers
-
NIH, NIDDK
Panelist
